BIOCARTIS news, videos and press releases - Page 6
For more news please use our advanced search feature.
BIOCARTIS - More news...
BIOCARTIS - More news...
- Biocartis Group NV: BIOCARTIS ANNOUNCES 2017 RESULTS AND 2018 OUTLOOK
- Biocartis Group NV: Biocartis Establishes R&D Center in the US
- Biocartis Group NV: European Union provides Biocartis with up to EUR 24m debt financing facility for infectious disease projects
- Biocartis Group NV: Disclosure of a transparency notification
- Biocartis Group NV: Biocartis to host webcast for announcement 2017 financial results on 1 March 2018
- Biocartis Group NV: Disclosure of a transparency notification
- Biocartis Group NV: Disclosure of a transparency notification
- Biocartis Group NV: Biocartis and Amgen Sign New Companion Diagnostic Agreement for Novel Oncology Compound
- Biocartis Group NV: Disclosure of a transparency notification
- Biocartis Group NV: Disclosure of outstanding voting securities
- Biocartis Group NV: Disclosure of a transparency notification
- Biocartis Group NV: Biocartis and Amgen Sign Companion Diagnostic Agreement for Idylla(TM) RAS Biomarker Tests
- Biocartis Group NV: Biocartis successfully raises EUR 80 million in an equity placement
- Biocartis Group NV: BIOCARTIS LAUNCHES EQUITY PLACEMENT
- Biocartis Group NV: Biocartis launches CE-marked IVD RAS liquid biopsy tests developed under partnership with Merck KGaA, Darmstadt, Germany
- Biocartis Group NV: BIOCARTIS Q3 2017 BUSINESS UPDATE
- Biocartis Group NV: BIOCARTIS Q3 2017 BUSINESS UPDATE
- Biocartis Group NV: Idylla(TM) Performance Data Presented by US Key Opinion Leaders at Association for Molecular Pathology 2017 Conference
- Biocartis Group NV: Idylla(TM) Performance Data Presented by US Key Opinion Leaders at Association for Molecular Pathology 2017 Conference
- Biocartis Group NV: Disclosure of a transparency notification
- Biocartis Group NV: Disclosure of a transparency notification
- Biocartis Group NV: Disclosure of outstanding voting securities
- Biocartis Group NV: Disclosure of outstanding voting securities
- Biocartis Group NV: Disclosure of a transparency notification
- Biocartis Group NV: Genomic Health and Biocartis Announce Agreement to Develop an Idylla(TM) IVD Oncotype DX® Breast Cancer Test to Broaden Global Patient Access
- Biocartis Group NV: Results of the extraordinary shareholders' meeting held on 11 September 2017
- Biocartis Group NV: Results of the extraordinary shareholders' meeting held on 11 September 2017
- Biocartis Group NV: Biocartis announces H1 2017 results
- Biocartis Group NV: Biocartis announces H1 2017 results
- Biocartis Group NV: Idylla(TM) Respiratory (IFV-RSV) Panel receives 510(k) clearance by US FDA
